HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS forecast for Arcturus Therapeutics to a loss of $0.87 per share from a projected loss of $0.94, while estimating a $3.46 per-share loss for full-year 2026.
• Arcturus recently reported a Q2 EPS loss of $0.84, beating consensus estimates for a $1.00 loss, but revenue of $2.96 million fell short of the $3.11 million estimate.
• The stock has a “Moderate Buy” consensus rating and an average price target of $24.25, despite trading at $7.60 and posting sharply negative profitability metrics; institutional investors own 94.54% of shares.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Arcturus Therapeutics in a research note issued on Tuesday, August 11th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of ($0.87) for the quarter, up from their previous forecast of ($0.94). The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Arcturus Therapeutics' Q4 2026 earnings at ($0.76) EPS, FY2026 earnings at ($3.46) EPS, FY2027 earnings at ($3.37) EPS, FY2028 earnings at ($3.31) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $5.63 EPS.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The business had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million.

Several other analysts have also recently issued reports on ARCT. Weiss Ratings restated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded Arcturus Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $7.60 on Thursday. The company has a market capitalization of $216.01 million, a price-to-earnings ratio of -2.30 and a beta of 2.39. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $24.17. The stock has a 50-day simple moving average of $6.75 and a 200 day simple moving average of $7.39.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Heartland Advisors Inc. bought a new stake in Arcturus Therapeutics in the second quarter valued at $1,474,000. Green Alpha Advisors LLC bought a new position in shares of Arcturus Therapeutics during the second quarter worth about $182,000. Diversify Advisory Services LLC bought a new position in shares of Arcturus Therapeutics during the second quarter worth about $91,000. BlackRock Inc. acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter worth about $17,566,000. Finally, Deutsche Bank AG acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter worth about $195,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source